DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

Nyheder

BioFIT and MedFIT – 3-4 December 2024 – discount rate of 20% 06 May 2024

We are happy to tell you that we have entered cooperation with BioFIT and MedFIT for the 2024 conference... Read more

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer 02 May 2024

Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR),... Read more

NLSDays Nordic Star Pitch Competition is NOW OPEN for applications 01 May 2024

As Dansk Biotek has been a supporter for NLSDays 2024 in Malmö, I’m happily sharing with you that... Read more

What is the right pay for biotech jobs? 23 April 2024

Participate now in The Danish Biotech Salary Survey 2024 to find out. The Danish Biotech Salary Survey... Read more

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer 19 April 2024

Oslo, Norway, April 19, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical... Read more

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) 17 April 2024

Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:... Read more

Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss 17 April 2024

Gubra announces the selection of a development candidate and unveils urocortin-2 (UCN2) as a novel anti-obesity... Read more

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate 16 April 2024

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more

Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol As A Treatment For Niemann-Pick Disease Type C At The SIMD 45th Annual Meeting 15 April 2024

ELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)... Read more

Copyright 2024 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design